Want to see SE:EXPRS2 full AI Analyst Report?

ExpreS2ion Biotech Holding AB (EXPRS2) Price & Analysis

0 Followers

EXPRS2 Stock Chart & Stats

kr17.10

-kr1.20(-4.51%)

At close: Mar 06 4:00 PM EST

kr17.10

-kr1.20(-4.51%)

Day’s Range― - ―

52-Week Rangekr1.10 - kr8.16

Previous CloseN/A

Volume135.00

Average Volume (3M)175.34K

Market Cap

kr32.06M

Enterprise Valuekr22.17

Total Cash (Recent Filing)kr34.38M

Total Debt (Recent Filing)kr1.45M

Price to Earnings (P/E)―

Beta1.40

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-6.83

Shares Outstanding23,748,983

10 Day Avg. Volume154,609

30 Day Avg. Volume175,344

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-9.64

Revenue Forecast (FY)kr7.30M

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low leverage limits refinancing pressure and preserves financial flexibility. This gives ExpreS2ion more room to fund platform development or pursue partnerships without the balance-sheet constraints associated with substantial debt.

Improving TTM RevenueRecent revenue improvement indicates continued customer demand for the company’s offerings despite historical volatility. Sustained growth could help absorb fixed costs and improve operating leverage if the platform gains broader adoption.

Multiple Platform Monetization RoutesThe ExpreS2 platform can generate income through services, licenses and collaborations rather than relying on one commercial channel. This flexibility may broaden customer access and create several paths to recurring or milestone-linked revenue.

Bears Say

Persistent UnprofitabilityNegative gross profitability and large operating losses show that current revenue does not cover the cost base. Without substantial improvement in pricing, utilization or scale, the business has limited evidence of an economically sustainable model.

Sustained Cash BurnOngoing operating and free-cash-flow deficits require continued funding of normal operations and development activities. This increases dependence on external financing and can constrain investment or dilute existing holders over the medium term.

Eroding Capital BaseDeclining equity alongside strongly negative returns indicates that losses are consuming the capital base rather than generating value. If funding needs persist, further capital raises or dilution may be required to maintain operations.

EXPRS2 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was kr1.10 and its highest was kr8.16 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is kr32.06M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is Nov 12, 2026 which is in 64 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Aug 20, 2026. The company reported -kr0.269 earnings per share for the quarter.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 23,748,983 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -kr0.269 in its last earnings report. Following the earnings report the stock price went down -0.717%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in SE:EXPRS2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.